290 related articles for article (PubMed ID: 23955284)
1. Targeting survivin in cancer: novel drug development approaches.
Groner B; Weiss A
BioDrugs; 2014 Feb; 28(1):27-39. PubMed ID: 23955284
[TBL] [Abstract][Full Text] [Related]
2. Increasing the range of drug targets: interacting peptides provide leads for the development of oncoprotein inhibitors.
Groner B; Weber A; Mack L
Bioengineered; 2012; 3(6):320-5. PubMed ID: 22825353
[TBL] [Abstract][Full Text] [Related]
3. Monitoring survivin expression in cancer: implications for prognosis and therapy.
Santa Cruz Guindalini R; Mathias Machado MC; Garicochea B
Mol Diagn Ther; 2013 Dec; 17(6):331-42. PubMed ID: 23912862
[TBL] [Abstract][Full Text] [Related]
4. Survivin as a Potential Target for Cancer Therapy.
Soleimanpour E; Babaei E
Asian Pac J Cancer Prev; 2015; 16(15):6187-91. PubMed ID: 26434815
[TBL] [Abstract][Full Text] [Related]
5. Survivin: A molecular biomarker in cancer.
Jaiswal PK; Goel A; Mittal RD
Indian J Med Res; 2015 Apr; 141(4):389-97. PubMed ID: 26112839
[TBL] [Abstract][Full Text] [Related]
6. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers.
Singh N; Krishnakumar S; Kanwar RK; Cheung CH; Kanwar JR
Drug Discov Today; 2015 May; 20(5):578-87. PubMed ID: 25433305
[TBL] [Abstract][Full Text] [Related]
7. Is survivin the potential Achilles' heel of cancer?
Lladser A; Sanhueza C; Kiessling R; Quest AF
Adv Cancer Res; 2011; 111():1-37. PubMed ID: 21704829
[TBL] [Abstract][Full Text] [Related]
8. Survivin as a preferential target for cancer therapy.
Mobahat M; Narendran A; Riabowol K
Int J Mol Sci; 2014 Feb; 15(2):2494-516. PubMed ID: 24531137
[TBL] [Abstract][Full Text] [Related]
9. Survivin as a prognostic/predictive marker and molecular target in cancer therapy.
Rödel F; Sprenger T; Kaina B; Liersch T; Rödel C; Fulda S; Hehlgans S
Curr Med Chem; 2012; 19(22):3679-88. PubMed ID: 22680927
[TBL] [Abstract][Full Text] [Related]
10. Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition.
Liu X; Gao R; Dong Y; Gao L; Zhao Y; Zhao L; Zhao X; Zhang H
BMC Cancer; 2010 Aug; 10():418. PubMed ID: 20698994
[TBL] [Abstract][Full Text] [Related]
11. Clinico-pathologic relevance of Survivin splice variant expression in cancer.
Necochea-Campion Rd; Chen CS; Mirshahidi S; Howard FD; Wall NR
Cancer Lett; 2013 Oct; 339(2):167-74. PubMed ID: 23791888
[TBL] [Abstract][Full Text] [Related]
12. Treat cancers by targeting survivin: just a dream or future reality?
Coumar MS; Tsai FY; Kanwar JR; Sarvagalla S; Cheung CH
Cancer Treat Rev; 2013 Nov; 39(7):802-11. PubMed ID: 23453862
[TBL] [Abstract][Full Text] [Related]
13. Small Molecule Inhibitors Targeting the "Undruggable" Survivin: The Past, Present, and Future from a Medicinal Chemist's Perspective.
Cui Q; Huang C; Liu JY; Zhang JT
J Med Chem; 2023 Dec; 66(24):16515-16545. PubMed ID: 38092421
[TBL] [Abstract][Full Text] [Related]
14. Targeting of the anti-apoptotic gene survivin in human thyroid carcinoma.
Chen Z; Liu N; Zhu G; Dralle H; Hoang-Vu C
Int J Mol Med; 2012 Sep; 30(3):465-72. PubMed ID: 22751750
[TBL] [Abstract][Full Text] [Related]
15. Antisense inhibition of survivin expression as a cancer therapeutic.
Carrasco RA; Stamm NB; Marcusson E; Sandusky G; Iversen P; Patel BK
Mol Cancer Ther; 2011 Feb; 10(2):221-32. PubMed ID: 21216939
[TBL] [Abstract][Full Text] [Related]
16. Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastases.
Kedinger V; Meulle A; Zounib O; Bonnet ME; Gossart JB; Benoit E; Messmer M; Shankaranarayanan P; Behr JP; Erbacher P; Bolcato-Bellemin AL
BMC Cancer; 2013 Jul; 13():338. PubMed ID: 23835136
[TBL] [Abstract][Full Text] [Related]
17. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin.
Kelly RJ; Lopez-Chavez A; Citrin D; Janik JE; Morris JC
Mol Cancer; 2011 Apr; 10():35. PubMed ID: 21470426
[TBL] [Abstract][Full Text] [Related]
18. Survivin in survival of hepatocellular carcinoma.
Su C
Cancer Lett; 2016 Sep; 379(2):184-90. PubMed ID: 26118774
[TBL] [Abstract][Full Text] [Related]
19. A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.
Ling X; Cao S; Cheng Q; Keefe JT; Rustum YM; Li F
PLoS One; 2012; 7(9):e45571. PubMed ID: 23029106
[TBL] [Abstract][Full Text] [Related]
20. Nanotechnology based platforms for survivin targeted drug discovery.
Samarasinghe RM; Gibbons J; Kanwar RK; Kanwar JR
Expert Opin Drug Discov; 2012 Nov; 7(11):1083-92. PubMed ID: 22950742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
